Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation

Detalles Bibliográficos
Autores principales: Lee, Jong-Mi, Ahn, Ari, Min, Eun Jeong, Lee, Sung-Eun, Kim, Myungshin, Kim, Yonggoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293273/
https://www.ncbi.nlm.nih.gov/pubmed/37365186
http://dx.doi.org/10.1038/s41408-023-00867-x
_version_ 1785062965789065216
author Lee, Jong-Mi
Ahn, Ari
Min, Eun Jeong
Lee, Sung-Eun
Kim, Myungshin
Kim, Yonggoo
author_facet Lee, Jong-Mi
Ahn, Ari
Min, Eun Jeong
Lee, Sung-Eun
Kim, Myungshin
Kim, Yonggoo
author_sort Lee, Jong-Mi
collection PubMed
description
format Online
Article
Text
id pubmed-10293273
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-102932732023-06-28 Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation Lee, Jong-Mi Ahn, Ari Min, Eun Jeong Lee, Sung-Eun Kim, Myungshin Kim, Yonggoo Blood Cancer J Correspondence Nature Publishing Group UK 2023-06-26 /pmc/articles/PMC10293273/ /pubmed/37365186 http://dx.doi.org/10.1038/s41408-023-00867-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Correspondence
Lee, Jong-Mi
Ahn, Ari
Min, Eun Jeong
Lee, Sung-Eun
Kim, Myungshin
Kim, Yonggoo
Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation
title Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation
title_full Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation
title_fullStr Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation
title_full_unstemmed Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation
title_short Monitoring measurable residual disease and chimerism in patients with JAK2 V617F-positive myelofibrosis after allogeneic hematopoietic cell transplantation
title_sort monitoring measurable residual disease and chimerism in patients with jak2 v617f-positive myelofibrosis after allogeneic hematopoietic cell transplantation
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10293273/
https://www.ncbi.nlm.nih.gov/pubmed/37365186
http://dx.doi.org/10.1038/s41408-023-00867-x
work_keys_str_mv AT leejongmi monitoringmeasurableresidualdiseaseandchimerisminpatientswithjak2v617fpositivemyelofibrosisafterallogeneichematopoieticcelltransplantation
AT ahnari monitoringmeasurableresidualdiseaseandchimerisminpatientswithjak2v617fpositivemyelofibrosisafterallogeneichematopoieticcelltransplantation
AT mineunjeong monitoringmeasurableresidualdiseaseandchimerisminpatientswithjak2v617fpositivemyelofibrosisafterallogeneichematopoieticcelltransplantation
AT leesungeun monitoringmeasurableresidualdiseaseandchimerisminpatientswithjak2v617fpositivemyelofibrosisafterallogeneichematopoieticcelltransplantation
AT kimmyungshin monitoringmeasurableresidualdiseaseandchimerisminpatientswithjak2v617fpositivemyelofibrosisafterallogeneichematopoieticcelltransplantation
AT kimyonggoo monitoringmeasurableresidualdiseaseandchimerisminpatientswithjak2v617fpositivemyelofibrosisafterallogeneichematopoieticcelltransplantation

Ejemplares similares